|
Re: BCA fighting to keep tdm1 off market
Joe, maybe time spend on the phone with Genentech, trying to get Irene back on t-dm1 medication wasn't all for naught. Roche, today during a conference call announced that they will file this year for t-dm1 3L approval based on strong data results seen from the phaseII trial.
The FDA, according to Pascal Soriot, head of the Basel, Switzerland -based company's drug unit: “They accepted the data and with great enthusiasm.”
|